---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-25-000087"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:56:25.446086+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits

## Summary
- Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.
- Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.
- Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.
- Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.
- CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period.

## SEC filing metadata
- accession: 0001376339-25-000087
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/0001376339-25-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/mdxg-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-25-000087
- JSON: https://secwatch.observer/filing/0001376339-25-000087.json
- Plain text: https://secwatch.observer/filing/0001376339-25-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.